A Phase I study of Everolimus and Bendamustine in Patients with relapsed/refractory lymphoid hematologic malignancies

ConclusionThe combination of everolimus and bendamustine appeared to be well-tolerated and relatively efficacious.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research